NCT07155629View on ClinicalTrials.gov

Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

381

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

August 31, 2030

Study Completion Date

August 31, 2030

Conditions
Pancreatic Cancer Resectable
Interventions
DRUG

mFOLFIRINOX neoadjuvant chemotherapy / Nab-paclitaxel and gemcitabine

The benefits of neoadjuvant chemotherapy before surgery in a prospective multicenter randomized setting for resectable left-sided pancreatic cancer patients.

Trial Locations (2)

90220

Oulu University Hospital, Oulu

00290

Helsinki University Central Hospital, Helsinki

All Listed Sponsors
collaborator

Oulu University Hospital

OTHER

lead

Helsinki University Central Hospital

OTHER